PSS15 THE COST-EFFECTIVENESS OF RANIBIZUMAB (LUCENTIS) IN TREATING PATIENTS WITH PREDOMINANTLY CLASSIC, MINIMALLY CLASSIC, AND OCCULT NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (AMD)
May 1, 2008, 00:00
10.1016/S1098-3015(10)70910-4
https://www.valueinhealthjournal.com/article/S1098-3015(10)70910-4/fulltext
Title :
PSS15 THE COST-EFFECTIVENESS OF RANIBIZUMAB (LUCENTIS) IN TREATING PATIENTS WITH PREDOMINANTLY CLASSIC, MINIMALLY CLASSIC, AND OCCULT NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (AMD)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)70910-4&doi=10.1016/S1098-3015(10)70910-4
First page :
Section Title :
Open access? :
No
Section Order :
663